Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Phase I study of GW572016 (lap...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV).
Bibliographic Details
Main Authors:
Midgley, R
,
Flaherty, K
,
Haller, D
,
Versola, M
,
Smith, D
,
Koch, K
,
Pandite, L
,
Kerr, D
,
O'Dwyer, P
,
Middleton, MR
Format:
Conference item
Published:
2005
Holdings
Description
Similar Items
Staff View
Similar Items
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
by: Midgley, R, et al.
Published: (2007)
Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).
by: Diaz-Rubio, E, et al.
Published: (2004)
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
by: Takeshi Kawakami, et al.
Published: (2023-01-01)
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
by: Letizia Procaccio, et al.
Published: (2023-07-01)
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
by: Li-Tzong Chen, et al.
Published: (2019-07-01)